Significant Ownership of SPHERA FUNDS MANAGEMENT LTD.

Signature - Title
/s/ Adi Hanetz - Adi Hanetz / General Counsel
Location
Tel Aviv, Israel
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by SPHERA FUNDS MANAGEMENT LTD..

Notify me when SPHERA FUNDS MANAGEMENT LTD. files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of SPHERA FUNDS MANAGEMENT LTD.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PMN ProMIS Neurosciences Inc. Common Shares, no par value per share 7.8% $75,893 -$1,235,385 180,698 -94% Sphera Funds Management Ltd. 31 Dec 2025
CMMB Chemomab Therapeutics Ltd. American Depository Shares, each representing twenty (20) ordinary shares, no par value 4.8% $1,152,548 900,428 Sphera Funds Management Ltd. 31 Mar 2025
SKYE Skye Bioscience, Inc. Common Stock, Par Value $0.001 4.8% $2,952,706 1,476,353 Sphera Funds Management Ltd. 31 Mar 2025
OTLK Outlook Therapeutics, Inc. Common Stock, par value $0.01 per share 4.7% $4,983,092 +$920,239 3,153,856 +23% Sphera Funds Management Ltd. 31 Dec 2025

Schedules 13D/G Reported by SPHERA FUNDS MANAGEMENT LTD.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.